MapLight Therapeutics Inc.
(NASDAQ:MPLT) stock is trading lower on Monday after the company reported topline data from its Phase 2 ZEPHYR trial of ML-007C-MA, an oral M1/M4 muscarinic agonist (betovumeline) co-formulated with a peripherally acting anticholinergic (fesoterodine), in adults with an acute exacerbation of schizophrenia.
The study successfully met its primary endpoint at Week 5, as the 210/3 mg twice-daily dose achieved a statistically significant and clinically meaningful reduction in Positive and Negative Syndrome Scale (PANSS) total scores versus placebo.
PANSS measures the severity of symptoms in schizophrenia patients.
It evaluates positive symptoms (excess functions like hallucinations), negative symptoms (loss of normal functions), and general psychopathology.
